| Book nr | Presentation / publication | Title                                                                 | Sessions / Topic | Presenter       |
|---------|----------------------------|----------------------------------------------------------------------|------------------|-----------------|
|         | P. Ramakrishnan Geethakumari | Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV-associated Aggressive B-cell Non-Hodgkin Lymphomas | Epidemiology     |                 |
| 157     | POSTER                     | TESTICULAR LARGE B-CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B-CELL LYMPHOMA | Biology          | A. Rivas-Delgado |
| 158     | POSTER                     | Subgrouping of Burkitt lymphoma variants by DNA methylation is driven by an EBV-associated epigenotype | Biology          | S. Glaser       |
| 159     | POSTER                     | A transposable element atlas of aggressive B-cell non-Hodgkin lymphomas defines novel classifications of Burkitt lymphoma independent of EBV status | Biology          | B. Singh        |
| 160     | POSTER                     | Characterization of the genetic and epigenetic landscape of B-cell neoplasms with IG::BCL3-translocation | Biology          | C. Drewes       |
| 161     | POSTER                     |                                                                          |                  |                 |
| No. | Poster Type | Title                                                                                                                                  | Field      | Authors            |
|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|
| 162 | POSTER      | Genomic characterization of lymphomas in patients with inborn errors of immunity                                                          | Biology    | Q. Pan-Hammarström |
| 163 | POSTER      | Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib | Biology    | J. A. Woyach       |
| 164 | POSTER      | The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation and small nucleolar RNA processing to sustain the survival of DLBCL cells | Biology    | G. Sartori         |
| 165 | POSTER      | Alpha-ketoglutarate Suppresses Tumor Growth of Diffuse Large B-cell Lymphoma by Inducing Ferroptosis                                    | Biology    | Y. Cai             |
| 166 | POSTER      | CTPS1 acts as a prognostic biomarker and therapeutic target in mantle cell lymphoma                                                        | Biology    | J. Liang           |
| 167 | POSTER      | Lipid metabolism reprogramming roles in mantel cell lymphoma growth and survival                                                        | Biology    | J. Liang           |
| 168 | POSTER      | Deciphering the role of MSI2 as a regulator of stem-like properties in mantle cell lymphoma                                          | Biology    | V. Amador          |
| 169 | POSTER      | Lymph node location and retention properties of DC-SIGN engagement with the Immunoglobulin Oligomannoses of Follicular Lymphoma      | Biology    | F. Forconi         |
| 170 | POSTER      | CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through increasing BNIP3 expression | Biology    | J. Liang           |
| 171 | POSTER      | Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon-beta (IFN-β) Gene Expression in Classical Hodgkin Lymphoma (cHL) | Biology    | I. Xagoraris       |

**Microenvironment**

| No. | Poster Type | Title                                                                                                                                  | Field      | Authors            |
|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|
| 172 | POSTER      | Unraveling the mechanisms of c-MYC-mediated escape from antibody and T-cell based anti-tumor immune attack in B-cell malignancies | Microenviron| V. de Jonge       |
| Page | POSTER Number | Title                                                                                                            | Authors                                                                 | Microenvironment |
|------|---------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------|
| 173  | 173           | Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapies | C. Pagès-Geli                                                         | Microenvironment |
| 174  | 174           | The Immunobiology of histologic transformation in follicular lymphoma: a multi-omic case-control study              | J. C. Villasboas                                                       | Microenvironment |
| 175  | 175           | Spatial transcriptomic profiling: The “Next Generation Diagnosis” distinguishing between EBV+ lymphoproliferations with Hodgkin-like features | M. R Pugh                                                             | Microenvironment |
| 176  | 176           | Combined single-cell and spatially-resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organization | S. Dietrich                                                           | Microenvironment |
| 177  | 177           | Digital spatial profiling of the tumor microenvironment in Hodgkin-like adult T-cell leukemia/lymphoma           | M. Takeuchi                                                           | Microenvironment |
| 178  | 178           | Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant proliferative drive CLL patients    | Y. Sha                                                                | Microenvironment |
| 179  | 179           | Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometry. | A. Niu                                                                | Microenvironment |
| 180  | 180           | Prognostic values of circulating TREM2+ and ARG1+ Mreg cells in adults with treatment-naïve diffuse large B-cell lymphoma | H. Wang                                                               | Microenvironment |
| 181  | 181           | Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma | N. L. Roberts                                                        | Microenvironment |
| 182  | 182           | Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma                        | A. C Kwang                                                            | Microenvironment |
| Poster | Title | Authors |
|-------|-------|---------|
| 183   | T cell CD62L expression following nivolumab therapy is associated with response to rituximab-nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study | A. Barraclough |
| 184   | RHOA deficiency drives decreased CD19 expression and immune dysregulation in CAR-T resistant diffuse large B-cell lymphoma | A. Newsam |
| 185   | Shelter in place: Live CLL cells inside the bone marrow fibroblasts and its implication in drug resistance | Y. L. Wang |
| 186   | Degradation of CD47-SIRPα axis by pomalidomide potentiates CD20 antibody-dependent cellular phagocytosis against B-cell lymphoma | H. Guo |
| 187   | Targeting monocytic-myeloid suppressor cells through CSF1R-blockade enhances CD19-CAR T-cell response in DLBCL | P. Gödel |
| 188   | SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T-cell activity against large B-cell lymphoma | M. R Green |
| 189   | Prognostic impact of HLA-I neoantigen-specific CD8+ T cells in limited-stage follicular lymphoma | J. W. Tobin |
| 190   | Metabolic reprograming of exhausted intratumoral CD8+ T-cell underlies anti-tumor activity of SUMOylation inhibitors in Large B Cell Lymphoma | A. A. Merchant |
| 191   | Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse | F. Swain |
| 192   | Enhancing T-cell responses to GCB-like lymphomas with immune-checkpoint-blockade-based therapies | R. Zappasodi |
| 193 | POSTER | Itk inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients | Microenvironment | N. Ding |
| 194 | POSTER | Determinants of response to T-cell stimulation by CD27 antibody therapy in lymphoma: The RiVa trial | Microenvironment | S. H. Lim |
| 195 | POSTER | Gut microbiome in DLBCL patients undergoing first-line R-CHOP regimen – The Oncopassport Study | Microenvironment | V. Stefoni |
| 195 bis | POSTER | Plasma Protein Profiling using Multiplex Extension Assay in DLBCL. A descriptive study exploring plasma protein pattern evolution in DLBCL treated with R-CHOP. | Microenvironment | A. H. Abu Sabaa |
| 196 | POSTER | Microbiota diversity in patients with Diffuse Large B-Cell Lymphoma and Immune-Privileged Sites Lymphoma | Microenvironment | V. Herman |
| 197 | POSTER | TAYloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B-cell NHL | Microenvironment | F. Gava |
| 198 | POSTER | Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non-Hodgkin lymphoma | Microenvironment | N. Gower |

**Translational studies, B-cell lymphomas**

| 199 | POSTER | Identification of an activated /memory B-cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients. | Translational B cell | C. Laurent |
| 200 | POSTER | A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial | Translational B cell | P. Mozas |
| 201 | POSTER | Genetic Alterations in Follicular Lymphoma Predict Response to Very Low Dose Radiotherapy | Translational B cell | N. A. Wijetunga |
| Poster ID | Type   | Title                                                                 | Author(s)                  |
|-----------|--------|----------------------------------------------------------------------|----------------------------|
| 202       | POSTER | Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma | M. B. H. Enemark           |
| 203       | POSTER | Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non-H.pylori Helicobacter using multiplex PCR: a retrospective analysis | M. Raderer                 |
| 204       | POSTER | Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real-World Diffuse Large B-cell Lymphoma Population | W. Alduaj                  |
| 205       | POSTER | Identification of biomarkers for predicting central nervous system involvement in patients with diffuse large B-cell lymphoma | C. Pagès-Geli              |
| 206       | POSTER | Predicting cell of origin from digitized images of hematoxylin and eosin-stained slides of diffuse large B-cell lymphomas using a cell-based deep-learning model | C. Laurent                 |
| 207       | POSTER | MYC negatively impacts treatment outcomes in stage II, but not stage I diffuse large B-cell lymphoma | V. de Jonge                |
| 208       | POSTER | A sub-population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL) | A. D. Jeyasekharan         |
| 209       | POSTER | Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor | Z. Shi                     |
| 210       | POSTER | Biological and clinical relevance of CD79 protein and gene expression in diffuse large B-cell lymphoma | Y. Naoi                    |
| 211       | POSTER | Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis | H. Wan                     |
| POSTER | Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma | Translational B cell | R. R. Sarkar |
|--------|---------------------------------------------------------------------|----------------------|-------------|
| POSTER | Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia | Translational B cell | S. Mebwe Pachong |
| POSTER | Next Generation Sequencing in routine diagnostics of mature non-Hodgkin’s lymphomas. A single-center real-life data study | Translational B cell | M. F Breinholt |
| POSTER | Machine Learning-Based Stem Cell-Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B-Cell Lymphoma: Multi-Omics Data from Multicenter Studies | Translational B cell | L. Wang |
| POSTER | LONG-TERM FOLLOW-UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS TREATED IN THE NORDIC P[R]EBEN TRIAL | Translational B cell | T. Relander* |

**Translational studies, PTCL and cHL**

| POSTER | Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO-LINF study | Translational T/CHL | B. Casadei |
|--------|---------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------|
| POSTER | Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0. | Translational T/CHL | M. Federico |
| POSTER | Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profiles | Translational T/CHL | E. W. Y. Chang |
| POSTER | Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma | Translational T/CHL | I. Pal |
| POSTER | Serum Triglyceride and Apolipoprotein A1 as Biomarkers for Extranodal Natural Killer/T cell Lymphoma (ENKTL): A Multicenter Study | Translational T/CHL | Q. Cai |
| Session | Type  | Title                                                                                                                                                                                                 | Authors                  |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 222     | POSTER| Soluble immune checkpoints HVEM and TIM-3 are prognostic biomarkers for outcome in classical Hodgkin lymphoma                                                                                           | J. Ferdinandus          |
| 223     | POSTER| A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD courses.                                                  | S. Luminari             |
| 224     | POSTER| Deregulated hsa-miR-23a-3p and hsa-miR-148a-3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesis                                                                                | M. Giefing              |
| 225     | POSTER| STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response                             | I. Xagoraris             |
| 226     | POSTER| Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis                                                                                | M. D. Andersen          |

**Translational studies, liquid biopsy**

| Session | Type  | Title                                                                                                                                                                                                 | Authors                  |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 227     | POSTER| Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma                                                                                                | M. C. Pirosa             |
| 228     | POSTER| Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study                                                               | C. Rossi                 |
| 229     | POSTER| PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA.                                                    | A. Jiménez-Ubieto        |
| #  | POSTER | Title                                                                 | Authors               |
|----|--------|----------------------------------------------------------------------|-----------------------|
| 230| POSTER | Genetic characterization in tissue and cfDNA in marginal zone lymphomas | R. Diez-Feijóo        |
| 231| POSTER | Serial circulating tumor DNA sequencing reveals clonal dynamics and can offer treatment guidance in relapsed/refractory diffuse large B-cell lymphoma | J. M. Heger           |
| 232| POSTER | Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B-cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody | D. Soong              |
| 233| POSTER | Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B-Cell Lymphoma | J. Arzuaga-Mendez     |
| 234| POSTER | Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL) | J. Westin             |
| 235| POSTER | Clinical implications of ctDNA in predicting the genetic subtype, CNS involvement and outcomes of newly diagnosed diffuse large B cell lymphoma | J. Liang              |
| Session | Poster Type | Title | Authors |
|---------|-------------|-------|---------|
| 236     | Poster      | Molecular characterization of diffuse large-B cell lymphoma by liquid biopsy at diagnosis and during follow-up. OBO "Euroclonality-NGS group" & "Grupo Colaborativo Linfomas y SLP de CyL" | M. E. Sarasquete |
| 237     | Poster      | Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t-cell therapy in non-Hodgkin B cell lymphoma. | M. Bastos |
| 238     | Poster      | LIQUID BIOPSY FOR EARLY, NON-INVASIVE DIAGNOSIS OF EBV-POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGS | C. C. Chamba |
| 239     | Poster      | Clinical impact of Epstein–Barr virus DNA in aggressive NK-cell leukemia | A. Fujimoto |
| 240     | Poster      | Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T-cell lymphoma | J. Liang |
| 241     | Poster      | Cell-free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study | F. LEMONNIER |

**Imaging**
| Poster Number | Type   | Title                                                                 | Section   | Author            |
|---------------|--------|------------------------------------------------------------------------|-----------|-------------------|
| 242           | POSTER | The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial | Imaging   | L. Guerra         |
| 243           | POSTER | Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups) | Imaging   | C. Rossi          |
| 244           | POSTER | Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B-cell lymphoma (DLBCL) | Imaging   | J. T Shreve       |
| 245           | POSTER | An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG-avid lymphomas using a deep learning model | Imaging   | T. Xu             |
| 246           | POSTER | Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B-cell lymphoma (DLBCL) | Imaging   | A. M. Bock        |
| 247           | POSTER | Differences in baseline PET/CT lymphoma distribution patterns between DLBCL-NOS and high-risk DLBCL patients | Imaging   | K. J. Croese      |
| 248           | POSTER | Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials – A LYSA retrospective analysis | Imaging   | L. Pascal         |
| 249           | POSTER | Modification of Lugano Criteria by Pre-Infusion Tumor Kinetics Improves Early Survival Prediction for Lymphoma Patients Under Chimeric Antigen Receptor T-Cell Therapy | Imaging   | W. G Kunz         |
| 250           | POSTER | Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs – Data from International Prospective T-Cell Project 2.0 | Imaging   | T. Skrypets       |
| 251           | POSTER | Interim 3-Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL) | Imaging   | E. A Hawkes       |

**Hodgkin lymphoma**
| POSTER | Baseline-PET derived metrics are the most relevant factors for risk stratification in early-stage nonbulky HL: preliminary results of the RAFTING trial. | HL | A. Gallamini |
| POSTER | PET-Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma | HL | A. Moskowitz |
| POSTER | Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C) | HL | J. S Abramson |
| POSTER | Impact of PET-2 guided treatment de-escalation on time-to-recovery from cancer-related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study | HL | J. Ferdinandus |
| POSTER | Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage | HL | A. Santarsieri |
| POSTER | ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma – a multicentre, retrospective study | HL | M. R. Wilson |
| POSTER | Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi-institution cohort | HL | J. Svoboda |
| POSTER | BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma | HL | M. Carella |
| POSTER | Efficacy of brentuximab consolidation by metabolic response in an international real-world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT | HL | S. H Desai |
| POSTER | Toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group | HL | J. Ferdinandus |
| POSTER | Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma – Polish Lymphoma Research Group Study | HL | E. Paszkiewicz-Kozik |
| Poster # | Type  | Title                                                                                                                                                                                                 | Specialty       | Author            |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------------|
| 263     | POSTER| An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment                                           | HL              | D. Lavie         |
| 264     | POSTER| Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents.                                                                           | HL              | S. H Desai       |
| 265     | POSTER| Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors.                                         | HL              | C. Pellegrini    |
| 266     | POSTER| Secondary cancer is the leading cause of death 15 years or more after diagnosis of early-stage Hodgkin lymphoma                                                                                 | HL              | I. Lagerlöff     |
| 267     | POSTER| Overall survival and causes of death in elderly patients with Hodgkin lymphoma – a Norwegian population-based case-control study                                                                   | HL              | K. Lia           |

**Indolent lymphomas**

| Poster # | Type  | Title                                                                                                                                                                                                 | Specialty       | Author            |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------------|
| 268     | POSTER| Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma                                                             | Indolent lymphomas | X. Wang          |
| 269     | POSTER| Real-world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER-Medicare population                                                                               | Indolent lymphomas | D. Chihara       |
| 270     | POSTER| Analysis of Real-World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients                                                             | Indolent lymphomas | L. H Sehn        |
| 271     | POSTER| Real-World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)                                                                                       | Indolent lymphomas | C. Jacobson      |
| 272     | POSTER| The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL) – a SCHOLAR-5 analysis                                      | Indolent lymphomas | J. G. Gribben    |
| Page | Type   | Title                                                                 | Indolent lymphomas | Author          |
|------|--------|----------------------------------------------------------------------|--------------------|-----------------|
| 273  | POSTER | Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trial | Indolent lymphomas | L. Guerra       |
| 274  | POSTER | Treatment outcomes of Limited Stage Grade 3A Follicular Lymphoma       | Indolent lymphomas | R. R. Sarkar    |
| 275  | POSTER | Outcomes in primary gastrointestinal (GI) follicular lymphoma (FL): results from a multicenter analysis | Indolent lymphomas | F. St-Pierre    |
| 276  | POSTER | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | Indolent lymphomas | C. Ujjani       |
| 277  | POSTER | A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma | Indolent lymphomas | P. Strati       |
| 278  | POSTER | Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun study | Indolent lymphomas | J. M. Burke     |
| 279  | POSTER | The impact of CHOP versus bendamustine on bone mineral density in patients with follicular lymphoma enrolled in the GALLIUM study | Indolent lymphomas | P. Jensen       |
| 280  | POSTER | Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first-line immunochemotherapy: a real-world prospective study. | Indolent lymphomas | A. Salar Silvestre |
| 281  | POSTER | REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real-world prospective cohort. | Indolent lymphomas | C. Bommier      |
| 282  | POSTER | Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) | Indolent lymphomas | C. Thieblemont  |
| Poster | Title                                                                 | Indolent lymphomas | Authors       |
|--------|----------------------------------------------------------------------|-------------------|---------------|
| 283    | POSTER                                                                 | Indolent lymphomas | J. Zhu        |
| 284    | POSTER                                                                 | Indolent lymphomas | J. Trotman    |
| 285    | POSTER                                                                 | Indolent lymphomas | K. Tringale   |
| 286    | POSTER                                                                 | Indolent lymphomas | M. Raderer    |
| 287    | POSTER                                                                 | Indolent lymphomas | E. Toussaint  |
| 288    | POSTER                                                                 | Indolent lymphomas | N. L. Berinstein |
| 289    | POSTER                                                                 | Indolent lymphomas | A. Broccoli   |
| 290    | POSTER                                                                 | Indolent lymphomas | E. Domingo Domènech |
|        | **Extranodal lymphomas non MZL**                                       |                   |               |
| 291    | POSTER                                                                 | Extranodal Non MZL | K. R. Tringale |
| 292    | POSTER                                                                 | Extranodal Non MZL | Y. S. Choi    |
| Posteri nul | Induction (MATRix) Followed by Transplantation in Primary Central Nervous System Lymphoma. Experience of the GELTAMO (Grupo Español de Linfoma y Trasplante de Medula Ósea). | P. Lopez-Pereira |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 294 POSTER | Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients                                                                                       | B. S. Imber     |
| 295 POSTER | Bone Marrow Assessment may be Omitted in Newly Diagnosed Diffuse Large B-Cell Lymphomas with Primary CNS Involvement                                                                                       | F. Martin-Moro  |
| 296 POSTER | Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma                                                                   | J. H. Yi        |
| 297 POSTER | Preliminary results of penpulimab combined with RMA (rituximab, methotrexate, and cytarabine) for newly diagnosed primary central nervous system lymphoma (PCNSL)                                                | H. Shen         |
| 298 POSTER | Radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma                                                                                               | G. Cederquist   |
| 299 POSTER | Geriatric assessment scores: Predictors of prognosis and premature end of treatment in the MARTA and MARiTA study population of elderly PCNSL patients > 65 years                                              | A. Orbàn        |
| 300 POSTER | Primary Mediastinal B-cell Lymphoma, a nationwide real-life retrospective study from Fondazione Italiana Linfomi (FIL).                                                                                       | E. Iannitto     |
| 301 POSTER | REAL-LIFE EXPERIENCE WITH RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS | T. Vassilakopoulos |
| 302 POSTER | Axicabtagene ciloleucel (Axisel) for relapsed/refractory primary mediastinal B-cell lymphoma (r/r PMBCL) compared to DLBCL-NOS: A GLA/DRST registry study.                                                  | M. Schubert     |
| Poster # | Type  | Title                                                                                                                                                                                                 | DLBCL | Authors |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------|
| 303     | POSTER| Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)                                                               | Extranodal Non MZL | M. C. Pirosa |
| 304     | POSTER| Comparison Between aaIPI, LAB-PI, NCCN-IPI and GELTAMO-IPI to Predict Prognosis in Elderly Patients with Diffuse Large-B Cell Lymphoma who Undergo R-CHOP/R-miniCHOP | DLBCL | F. Martin-Moro |
| 305     | POSTER| Patient- versus clinician-reported symptoms in the POLARIX study                                                                                                                                        | DLBCL | C. A. Thompson |
| 306     | POSTER| Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study                                                                                     | DLBCL | B. Hu |
| 307     | POSTER| A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B-cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement | DLBCL | J. E. Haydu |
| 308     | POSTER| Pola-R-CHP vs. R-CHOEP in young patients with high-risk diffuse large B-cell lymphoma                                                                                                                   | DLBCL | G. Lenz |
| 309     | POSTER| Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: Interim analysis of COALITION | DLBCL | A. Minson |
| 310     | POSTER| Zanbrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line treatment for non-GCB diffuse large B-cell lymphoma: An updated analysis of efficacy and tolerability                                  | DLBCL | H. Zhu |
| 311     | POSTER| Ibrutinib + bortezomib + R-CHOP for higher-risk DLBCL: Feasibility, efficacy and molecular predictors                                                                                                   | DLBCL | S. Denker |
| 312     | POSTER| Pixantrone containing R-CPOP as firstline treatment in elderly DLBCL patients with congestive heart failure or high risk of anthracycline induced cardiotoxicity                                             | DLBCL | R. Marks |
| 313     | POSTER| Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL                                    | DLBCL | E. Verner |
| #  | Type   | Title                                                                 | Disease | Author          |
|----|--------|----------------------------------------------------------------------|---------|-----------------|
| 314| POSTER | The treatment of Burkitt lymphoma with the Berlin-Frankfurt-Münster protocol with rituximab and autologous transplantation | DLBCL   | A. Broccoli     |
| 315| POSTER | Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis | DLBCL   | H. Ghesquièrees |
| 316| POSTER | Trends in relative survival of Diffuse large B-cell lymphoma in Sweden in the era of targeted and cellular therapies | DLBCL   | K. Ekström Smedby |
| 317| POSTER | Defining Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL) Based on Survival Outcomes | DLBCL   | A. M Bock       |
| 318| POSTER | Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX | DLBCL   | C. Herbaux      |
| 319| POSTER | Comparison of real-world clinical outcomes in patients with relapsed/refractory large B-cell lymphoma treated with epcoritamab vs chemoimmunotherapy | DLBCL   | A. Ip           |
| 320| POSTER | Novel therapies for the treatment of relapsed/refractory aggressive B-cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group | DLBCL   | M. Bastos-Oreiro |
| 321| POSTER | Venetoclax combined with R-ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy | DLBCL   | P. F. Caimi     |
| 322| POSTER | Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non-Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR). | DLBCL   | L. FORNECKER    |
| 323| POSTER | Five-year efficacy and safety of tafasitabam in patients with relapsed or refractory DLBCL: Final results from the Phase II L-MIND study | DLBCL   | J. Duell        |
| 324| POSTER | Five-year subgroup analysis of tafasitamab + lenalidomide from the Phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma | DLBCL   | J. Duell        |
| POSTER | Tafasitamab plus lenalidomide versus standard of care as second-line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L-MIND (IN 2L-MIND) | DLBCL | L. H. Sehn |
|---|---|---|---|
| POSTER | Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non-Hodgkin lymphoma | DLBCL | Y. Koh |
| POSTER | Interim report from a phase 2 multicenter study of anti-PD-1 antibody (penpulimab) plus lenalidomide, rituximab, gemcitabine and oxaliplatin in Relapsed/ Refractory DLBCL | DLBCL | J. Liang |
| POSTER | Predictors of long-term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma | DLBCL | D. J Landsburg |
| POSTER | Autologous hematopoietic cell transplantation (autoHCT) for T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party study | DLBCL | S. Renders |
| POSTER | Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor-modified T cells | DLBCL | D. J Landsburg |
| POSTER | Prognostic factors for cellular therapies - CART and allogeneic SCT - in relapsed /refractory large B cell lymphoma (LBCL) | DLBCL | B. Glass |
| POSTER | Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R/R large B-cell lymphoma | DLBCL | F. Morschhauser |
| POSTER | CAR T treatment access and outcomes in patients with large B-cell lymphoma according to ethnicity and socioeconomic deprivation | DLBCL | D. Dragoi |
| POSTER | Efficacy of Subcutaneous Epcoritamab vs Axi-cel in R/R DLBCL CAR T-Naive and CAR T-eligible patients: An Indirect Comparison | DLBCL | A. Wang |
| No. | Type | Title                                                                                                                                         | Disease | Author          |
|-----|------|-----------------------------------------------------------------------------------|---------|-----------------|
| 335 | POSTER | Efficacy and toxicity of CAR T-cell therapy in patients with primary and secondary central nervous system lymphoma – an analysis of the EBMT Lymphoma WP and the GoCART coalition | DLBCL   | B. Glaß         |
| 336 | POSTER | Treatment with anti CD19 CAR-T cells is safe and effective in patients with relapsed/refractory large B-cell lymphoma with active central nervous system involvement | DLBCL   | E. Robin Marieton |
| 337 | POSTER | Efficacy and safety of Axicabtagene ciloleucel (Axi-cel) for the treatment of relapse/refractory non-Hodgkin lymphoma: First real-world data in Chinese population | DLBCL   | W. L. Zhao      |
| 338 | POSTER | Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single-arm study | CLL     | M. Yi           |
| 339 | POSTER | Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database | CLL     | A. Tedeschi     |
| 340 | POSTER | Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials | CLL     | A. Tedeschi     |
| 341 | POSTER | Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health-related quality of life | CLL     | B. Eichhorst    |
| 342 | POSTER | Ibrutinib (Ibr) for treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison of 3 randomized phase 3 trials | CLL     | P. Ghia         |
| 343 | POSTER | Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome | CLL     | M. S. Davids    |
| 344 | POSTER | Safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with chronic lymphocytic leukemia - interim safety analysis of the ongoing phase II CLL-Frail trial | CLL     | F. Simon        |
| No. | Type | Title                                                                 | Disease | Presenter       |
|-----|------|----------------------------------------------------------------------|---------|-----------------|
| 345 | POSTER | A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL | CLL     | M. Shadman      |
| 346 | POSTER | Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients – a novel illness-death model study | MCL     | S. Ekberg       |
| 347 | POSTER | Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL) | MCL     | Y. Wang         |
| 348 | POSTER | Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study | MCL     | C. Visco        |
| 349 | POSTER | Secondary malignancies in mantle cell lymphoma patients – A nationwide population-based study in Sweden | MCL     | K. Abalo        |
| 350 | POSTER | How to choose between curative radiotherapy or chemotherapy in low stage MCL? – a population-based analysis of outcome in patients with stage I-II MCL in Sweden | MCL     | A. Albertsson-Lindblad |
| 351 | POSTER | Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG-MCL7-VALERIA) | MCL     | L. Meriranta    |
| 352 | POSTER | Long term follow-up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination. | MCL     | B. Tessoulin    |
| 353 | POSTER | Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory B-cell malignancies | MCL     | Y. Wang         |
| 354 | POSTER | Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group. | MCL     | S. Carras       |
| #  | Type | Title                                                                                                                                   | Disease | Author  |
|----|------|----------------------------------------------------------------------------------------------------------------------------------------|---------|---------|
| 355 | POSTER | Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial | MCL     | D. Villa|
| 356 | POSTER | Venetoclax based combination therapy does not overcome poor outcomes in BTKi-refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax | MCL     | D. S. Wallace|
| 357 | POSTER | Analysis of immune and high-risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy | MCL     | T. H. Pham|
| 358 | POSTER | Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment | MCL     | N. Ahmed|
| 359 | POSTER | Outcomes of Bridging and Salvage Radiotherapy in Relapsed or Refractory Mantle Cell Lymphoma Patients Undergoing CD19-Targeted CAR T-Cell Therapy | MCL     | C. Patel|

**PTCL**

| #  | Type | Title                                                                                                                                   | Disease | Author  |
|----|------|----------------------------------------------------------------------------------------------------------------------------------------|---------|---------|
| 360 | POSTER | Long term outcome of Peripheral T Cell Lymphomas:10y follow-up analysis of the International Prospective T Cell Project Network | PTCL    | M. Federico|
| 361 | POSTER | Diagnosis and management of adult T-cell leukemia/lymphoma in a Brazilian Cohort. T-cell Brazil Project.                               | PTCL    | C. S. Chiattone|
| 362 | POSTER | Newly diagnosed extranodal natural killer/T cell lymphoma (ENKTL) treated by anti-PD-1 antibody plus histone deacetylase inhibitor followed by P-GemOx regimen | PTCL    | H. Huang|
| 363 | POSTER | Enteropathy associated T-cell lymphoma: a population-based cohort study on incidence, treatment and outcome in The Netherlands | PTCL    | F. O. Meeuwes|
| 364 | POSTER | Comparison of CHOP-like with or without Tucidinostat in the first-line treatment of Peripheral T-cell lymphoma:a retrospective propensity score-matched study | PTCL    | X. Wen|
| Poster Number | Type   | Title                                                                 | Authors               |
|---------------|--------|----------------------------------------------------------------------|-----------------------|
| 365           | POSTER | Role of upfront autologous stem cell transplantation (ASCT) in adults with T-NHL in first complete remission (CR1): A systematic literature review and meta-analysis | P. L. Michelle       |
| 366           | POSTER | A randomized phase II trial of CHOP vs ICED and autologous stem cell transplantation in newly diagnosed T-cell lymphoma | K. H. Yoo             |
| 367           | POSTER | Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology | P. L. Zinzani         |
| 368           | POSTER | Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study | A. Fujimoto           |
| 369           | POSTER | Efficacy of anti-PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSAA | A. Marouf             |
| 370           | POSTER | Interim analysis of a prospective multicenter phase II study for advanced-stage or relapsed/refractory natural killer/T cell lymphoma | W. Liu                |
| 371           | POSTER | Pegaspargase and sintilimab for newly diagnosed, advanced stage natural killer T-cell lymphoma, nasal type: an open-label, single-arm, phase 2 study. | J. Xiong              |
| 372           | POSTER | Imatinib-induced complete and long-term sustained remission in chemotherapy-resistant systemic ALK-positive anaplastic large cell lymphoma | A. Pichler            |
| 373           | POSTER | Brigatinib in patients with ALK-positive anaplastic large cell lymphoma who have failed brentuximab vedotin | D. Sibon              |
| 374           | POSTER | Long-term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t-cell lymphoma | L. Bojanini           |
| 375 | POSTER | Combination of gemcitabine, pegasparagse, etoposide, and dexamethasone (GPED) in the treatment of advanced extranodal NK/T-cell lymphoma | PTCL | L. Wang |
| 376 | POSTER | Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T-cell lymphoma: an interim analysis from a prospective, observational, real-world study | PTCL | W. Zhao |
| 377 | POSTER | Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL | PTCL | S. S. Tolu |
| 378 | POSTER | Allogeneic transplantation in T-cell lymphoma: Lessons from the AATT study | PTCL | O. Tournilhac |

**Plasma cell neoplasms and amyloidosis**

| 379 | POSTER | Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas | MM / Plasma cell / Amyloidosis | B. Fregonese |
| 380 | POSTER | Radiation in a new era of Multiple Myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response | MM / Plasma cell / Amyloidosis | A. D. Dreyfuss |

**CAR-T (Cellular therapies)**

| 381 | POSTER | SAR444245, a non-alpha IL2, rescues chronic antigen and CAR-driven T-cell dysfunction | CAR-T (Cellular therapies) | M. R Green |
| Number | Type  | Title                                                                 | Journal                       | Author          |
|--------|-------|----------------------------------------------------------------------|-------------------------------|-----------------|
| 382    | POSTER| Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells | CAR-T (Cellular therapies)    | V. Vucinic      |
| 383    | POSTER| Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking. | CAR-T (Cellular therapies)    | V. Bachanova     |
| 384    | POSTER| The Italian CART-SIE real life multicenter observational study on Chimeric Antigen Receptor T-cell (CAR-T) therapy for large B-cell (LBCL) and mantle cell (MCL) lymphomas | CAR-T (Cellular therapies)    | A. Chiappella   |
| 385    | POSTER| 3-Year outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexu-cel in ZUMA-3 by age, prior therapies, and subsequent transplant | CAR-T (Cellular therapies)    | M. Topp         |
| 386    | POSTER| Matching-adjusted indirect comparison of axicabtagene ciloleucel vs mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments | CAR-T (Cellular therapies)    | S. Kanters      |
| 387    | POSTER| Outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe | CAR-T (Cellular therapies)    | S. Choquet      |
| Posters | Affiliation | Title                                                                 |
|---------|-------------|----------------------------------------------------------------------|
| 388     | POSTER      | Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study) |
| 389     | POSTER      | First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B-cell malignancies |
| 390     | POSTER      | A Phase I Study of CD19-targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma |
| 391     | POSTER      | Outcomes with bendamustine lymphodepletion and brexucabtagene autoleucel for mantle cell lymphoma |
| 392     | POSTER      | Reasons for Discordance Among Imaging-based Response Criteria In Lymphoma Patients Receiving CAR T-cell Therapy |
| 393     | POSTER      | CNS radiotherapy as bridging prior to CAR T-cell therapy for hematologic malignancies |
|   | POSTER | Title                                                                                     | Authors                                      |
|---|--------|-------------------------------------------------------------------------------------------|----------------------------------------------|
| 394 | POSTER | Developing CAR-T-sparing Radiotherapy - early dosimetric results                          | N. G. Mikhaeel                               |
| 395 | POSTER | Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma | H. Hubbeling                                 |
| 396 | POSTER | Predicting ICANS by means of plasma CAR-T cell derived extracellular vesicles in patients undergoing infusion of anti-CD19 CAR-T cells | F. De Felice                                 |
| 397 | POSTER | Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. A DESCAR-T study. | S. Vic                                       |
| 398 | POSTER | Neurotoxicity in patients with CNS lymphomas treated with CAR-T cell therapy. A LOC network study | C. Houillier                                 |
| 399 | POSTER | Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T Therapy | H. Reves                                     |
| POSTER | Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004 |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| POSTER | ‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein-to-vein time for LBCL patients treated with CAR T in the 3L+ setting |
| POSTER | Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program |

**Preclinical new drugs**

| POSTER | Drug-resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation |
|--------|----------------------------------------------------------------------------------------------------------------|
| POSTER | BTM 3566, a Novel Activator of the Mitochondrial Stress Response Induces Robust Therapeutic Responses in Diffuse Large B-cell Lymphoma in vitro and in vivo. |
| POSTER | MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemia |
| POSTER | Diffuse large B-cell lymphoma cell-cycle progression requires the cyclin-G associated kinase (GAK), a novel drug target from machine learning-enabled phenotypic screening |
| POSTER | BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models |
| POSTER | Differential ibrutinib sensitivity in Cd79b-mutant and wildtype subtypes of a novel Myd88-driven DLBCL mouse model | Preclinical New Drugs | G. Knittel |
| 409 POSTER | Synthesis and Preclinical Development of a Promising Novel Romidepsin Nanoparticle for the Treatment of Peripheral T-Cell Lymphoma (PTCL) | Preclinical New Drugs | O. A. O'Connor |
| 410 POSTER | Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos | Preclinical New Drugs | M. Zala |
| 411 POSTER | CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents. | Preclinical New Drugs | M. J. Thomenius |
| 412 POSTER | Orthotopic xenografts models in relapse/refractory lymphomas: a preclinical model for therapeutic, mechanistic and functional studies. | Preclinical New Drugs | E. Domingo Domenech |
| 413 POSTER | Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti-Tumor Activity in a Preclinical Model of Non-Hodgkin’s Lymphoma | Preclinical New Drugs | K. A. Logronio |
| 414 POSTER | Prolonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi-resistant mantle cell lymphoma | Preclinical New Drugs | N. Profitós-Pelejà |
| 415 POSTER | MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 Inhibitors in ibrutinib resistance mantle cell lymphoma | Preclinical New Drugs | O. Hershkovitz-Rokah |
| 416 POSTER | Interleukin-2-inducible kinase represents a novel therapeutic target for NK/T-cell lymphoma treatment | Preclinical New Drugs | J. Cao |
| 417 POSTER | Brincidofovir induces potent anti-tumor activity in MYC-driven Natural Killer/T-cell Lymphoma with loss of transcriptional repressor TLE1 | Preclinical New Drugs | J. Y. Chan |
| Poster Number | Type | Title                                                                 | Phase | Lead Author       |
|---------------|------|----------------------------------------------------------------------|-------|-------------------|
| 418           | POSTER | The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma. | Preclinical New Drugs | Y. Ye |
| 419           | POSTER | AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo | Preclinical New Drugs | J. Pahl |
| 420           | POSTER | Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1 | Phase I-II | M. Dreyling |
| 421           | POSTER | A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CAPITAL) | Phase I-II | D. Hodson |
| 422           | POSTER | A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies: waveLINE-006 | Phase I-II | P. L. Zinzani |
| 423           | POSTER | Updated follow-up of BELLWAVE-001: an open-label, single-arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies | Phase I-II | H. Eradat |
| 424           | POSTER | Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors | Phase I-II | A. Olszewski |
| 425           | POSTER | Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T-cell Lymphoma (PTCL): Early trial analysis | Phase I-II | P. L. Zinzani |
| 426           | POSTER | Proof of concept of NX-2127, a first-in-class Bruton's Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with DLBCL | Phase I-II | A. Danilov |
| 427           | POSTER | Zilovertamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): 14-month follow-up of the phase 1 waveLINE-001 study | Phase I-II | M. L Wang |
| Page | Type | Title                                                                 | Phase | Authors |
|------|------|----------------------------------------------------------------------|-------|---------|
| 428  | POSTER | Robust Bruton’s tyrosine kinase (BTK) degradation with NX-5948, an oral BTK degrader, in a first-in-human phase 1a trial in relapsed/refractory B cell malignancies | I-II  | K. Linton |
| 429  | POSTER | Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma | I-II  | C. Carlo-Stella |
| 430  | POSTER | Liposomal doxorubicin supercharge-containing frontline treatment for diffuse large B-cell lymphoma or classical Hodgkin lymphoma: preliminary results of a phase II study | I-II  | C. Giordano |
| 431  | POSTER | Phase 2 KEYNOTE-B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) | I-II  | A. McDonald |
| 432  | POSTER | Response-adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis | I-II  | R. C Lynch |
| 433  | POSTER | Phase 2 study to investigate the efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study | I-II  | W. S. Kim |
| 434  | POSTER | First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients with B-Cell Lymphoma | I-II  | E. A Hawkes |
| 435  | POSTER | Phase 1 trial of EO2463 peptide-based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non-Hodgkin lymphoma: EONHL1-20/SIDNEY | I-II  | A. A. Pinto |
| 436  | POSTER | Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check-point inhibitor (CPI). | I-II  | V. Bachanova |
| 437  | POSTER | Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL) | I-II  | C. J. Melani |
| POSTER |
|---------|
| CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (a-BCL): early safety and efficacy results from a phase 1b study | Phase I-II | J. Munoz |
| Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial | Phase I-II | T. Phillips |
| Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL) | Phase I-II | H. Lee |
| CCTG LY18-A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma - the RGDP-Venetoclax substudy | Phase I-II | S. Assouline |
| First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase I-II | H. Zhang |
| Tafasitamab lenalidomide in relapsed/refractory large B-cell lymphomas: a multicentric real-world French experience study | Phase I-II | J. PAILLASSA |
| Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varilumab combined with Nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma | Phase I-II | J. C. Villasboas |
| Combination of everolimus and itacitinib in patients with Hodgkin lymphoma relapsed/refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPI) | Phase I-II | J. Svoboda |
| Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non-Hodgkin lymphoma (R/R NHL): update of a Phase Ib study | Phase I-II | W. Townsend |
| Combination of the PD-1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B-cell Lymphoma: Results from a Phase I/II Study | Phase I-II | D. A. Bond |
| POSTER | Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study: | Phase I-II | E. A. Hawkes |
| POSTER | Risks and benefits of phase 1 clinical trials for patients with relapsed or refractory lymphoma, from 2008 to 2023. | Phase I-II | J. M. Michot |
| POSTER | Regulatory approvals and survival benefit for novel lymphoma drugs from 2013-2022 | Phase I-II | E. R. S. Cliff |
| POSTER | Association between Geriatric Impairments and Quality of Life in Older Adults with Lymphoma on Oral Targeted Therapies: A One-Year Prospective Study | Phase I-II | P. Torka |

**Pediatric / Young adults**

| POSTER | What drives pediatric Burkitt lymphoma? Timing events in the evolution of cancer using single-cell whole genome sequencing. | Pediatric / Young adults | A. Steemers |
| POSTER | Analyses of a patient with 3 sequential Post Transplant Lymphoproliferative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD. | Pediatric / Young adults | B. Y. Ngan |
| POSTER | Abbreviated whole-body MRI for follow-up in pediatric lymphoma: results of a multicenter prospective study | Pediatric / Young adults | B. J. Zheng |
| POSTER | Characterization of clonal evolution in pediatric lymphoma using single-cell transcriptomics. | Pediatric / Young adults | R. D’aulerio |

**Infections**
| 456 | POSTER | Predicting COVID-19 infection risk in lymphoma by immune monitoring | Infections | S. H Lim |
|-----|--------|---------------------------------------------------------------|-----------|--------|
| 457 | POSTER | Impact of COVID-19 infection on bispecific antibodies treatment in patients diagnosed with B-cell lymphoproliferative disorders | Infections | A. Serna |
| 458 | POSTER | Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report | Infections | J. Yang |